跳转至内容
Merck
CN

SML2617

Sigma-Aldrich

Celiprolol hydrochloride

≥98% (HPLC)

别名:

Celiprolol hydrochloride, (3-[3-Acetyl-4-(3-t-butylamino-2-hydroxypropoxy)phenyl]-2,1-diethylurea hydrochloride, NSC 324509, REV 5320A, ST 1396, Selecor, Tenoloc

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H33N3O4 · HCl
CAS号:
分子量:
415.95
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

H2O: 2 mg/mL, clear

储存温度

2-8°C

InChI

1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H

InChI key

VKJHTUVLJYWAEY-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Celiprolol is a selective adrenoceptor modulator that acts not only as a selective β1 receptor antagonist, but also as a β2 receptor partial agonist. Because of its of its β2 agonist activity, celiprolol lacks the typical side effects of the beta-blockers, such as bronchoconstriction, depression of left ventricular function, and peripheral vasoconstriction, making it a good candidate for patients with both cardiovascular and pulmonary disease. It is currently being investigated for treatment of vascular Ehlers-Danlos Syndrome (vEDS).

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

James J Nawarskas et al.
Cardiology in review, 25(5), 247-253 (2017-07-26)
Celiprolol is a β-blocker with a unique pharmacologic profile: it is a β1-andrenoceptor antagonist with partial β2 agonist activity. Given this combination of effects, celiprolol may be better described as a selective adrenoreceptor modulator. It has antihypertensive and antianginal properties
Lawrence H Kwon et al.
Journal of hypertension, 35(9), 1768-1777 (2017-06-27)
Not only is there a limited number of studies on the effects of vasodilator β-blocker (VBB) therapy on kidney function - specifically, glomerular filtration rate (GFR), serum creatinine (sCr) and proteinuria - but of those that have been reported, the
Jingjing Yu et al.
Journal of pharmaceutical sciences, 106(9), 2312-2325 (2017-04-18)
In recent years, an increasing number of clinical drug-drug interactions (DDIs) have been attributed to inhibition of intestinal organic anion-transporting polypeptides (OATPs); however, only a few of these DDI results were reflected in drug labels. This review aims to provide

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门